Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
The Mechanism of Action of CDK4/6 Inhibitors
SABCS 2017
Videos
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
Related Items
Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Final Results of NeoMONARCH: A Phase 2 Neoadjuvant Study of Abemaciclib in Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
A Phase 1b Study of Abemaciclib plus Pembrolizumab for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
US Treatment Patterns for Young Women with HR-Positive, HER2-Negative Metastatic Breast Cancer in the Era of CDK4/6 Inhibitors
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Phase 1-2 Trial of Pembrolizumab and Either Doxorubicin or an Aromatase Inhibitor for Triple-Negative or HR-Positive Metastatic Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Abemaciclib plus Standard Adjuvant ET versus Standard Adjuvant ET Alone in High-Risk Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Abemaciclib for the Treatment of Brain Metastases Secondary to HR-Positive Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
The Synergistic Antitumor Activity of Entinostat (MS-275) in Combination with Palbociclib (PD 0332991) in ER-Positive and TN Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
The Benefit of Abemaciclib in Prognostic Subgroups: An Exploratory Analysis of Combined Data from MONARCH 2 and 3
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Phase 2 Study of the Feasibility and Safety of Radium-223 Dichloride plus Hormonal Therapy and Denosumab for the Treatment of HR-Positive Breast Cancer with Bone-Dominant Metastasis
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us